EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
https://doi.org/10.21518/2079-701X-2017-14-40-45
Abstract
The HannaH study showed that neoadjuvante-adjuvant subcutaneous and intravenous trastuzumab have similar efficacy and tolerability in patients with early HER2-positive breast cancer. The analysis of the results of the subcutaneous and intravenous trastuzumab usage in Russian population showed the favorable association between tpCR anf EFS. tpCR achiviement is associated with clinical benefit in HER2 positive breast cancer. For patients with difficult venous access who do not require intravenous chemotherapy currently, Subcutaneous trastuzumab allows to receive effective treatment without the risk of complications, which involves catheterization of a Central vein.
About the Authors
E. V. Lubennikova
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
I. P. Ganshina
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine
A. N. Lud
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine
D. V. Komov
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
I. V. Kolyadina
Russian Medical Academy of Continuous Postgraduate Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
Y. V. Vishnevskaya
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine
I. K. Vorotnikov
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
D. L. Stroyakovsky
Moscow Municipal Oncology Hospital No.62
Russian Federation
Russian Federation
PhD in medicine
N. A. Savelov
Moscow Municipal Oncology Hospital No.62
Russian Federation
Russian Federation
V. F. Semiglazov
Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
MD, Prof., Corresponding Member of RAS.
Saint-Petersburg
А. G. Manikhas
Municipal Clinical Oncologic Health Center
Russian Federation
Russian Federation
MD.
Saint-Petersburg
А. V. Osheychik
Moscow Municipal Oncology Hospital No.62
Russian Federation
Russian Federation
T. B. Strelnikova
Moscow Municipal Oncology Hospital No.62
Russian Federation
Russian Federation
K. R. Zeynalova
State Azerbaijan Medical University
Russian Federation
Russian Federation
L. G. Zhukova
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD
References
1. Bittner B et al. Development of a subcutaneous formulation for trastuzumab-nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung, 2012, 62(09): 401-409.
2. Ismael G. et al. Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, openlabel, multicentre, randomised trial. The lancet oncology, 2012, 13(9): 869-878.
3. Jackisch C et al. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. European Journal of Cancer, 2016, 62: 62-75.
4. Pivot X et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Annals of oncology, 2014, 25(10): 1979-1987.
5. Kuensting LL et al. Difficult venous access in children: taking control. Journal of Emergency Nursing, 2009, 35(5): 419-424.
6. Paskett E. D. et al. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiology and Prevention Biomarkers, 2007, 16(4): 775-782.
7. Tagalakis V, Kahn SR, Libman M and Blostein M. The epidemiology of peripheral vein infusion thrombophlebitis: a critical review. Am. J. Med., 2002, 113: 146-51.
Review
For citations:
Lubennikova EV, Ganshina IP, Lud AN, Komov DV, Kolyadina IV, Vishnevskaya YV, Vorotnikov IK, Stroyakovsky DL, Savelov NA, Semiglazov VF, Manikhas АG, Osheychik АV, Strelnikova TB, Zeynalova KR, Zhukova LG. EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION. Meditsinskiy sovet = Medical Council. 2017;(14):40-45. (In Russ.) https://doi.org/10.21518/2079-701X-2017-14-40-45
Views:
697
Email this article 